Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

One step closer
October 2020
SHARING OPTIONS:

EDINBURGH, Scotland—Ingenza Ltd. reported on significant progress with regards to its efforts to develop a vaccine against the SARS-CoV-2 virus, work it has been conducting with researchers at Oxford University and the UK CPI, Wilton. The team was able to efficiently produce the receptor-binding domain of the SARS-CoV-2 spike protein using engineered yeast. When attached to a novel virus-like particle, the prototype vaccine was capable of triggering a strong immunogenic response in mice.
 
“It is a huge privilege to be involved with our collaborators on this project, and the progress we are making is extremely positive and exciting,” stated Ian Fotheringham, managing director of Ingenza. We are proud to be applying our expertise in sustainable and cost-effective biomanufacturing to this global crisis and look forward to helping the world’s scientists develop a novel COVID-19 vaccine.”

Back



PAGE UTILITIES


CONTACT US
DDNEWS
1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.